Logo

Galapagos Reports Completion of Patient Enrollment in P-II MANGROVE Trial of GLPG2737 for the Treatment of Polycystic Kidney Disease

Share this

Galapagos Reports Completion of Patient Enrollment in P-II MANGROVE Trial of GLPG2737 for the Treatment of Polycystic Kidney Disease

Shots:

  • The company has completed the patient recruitment in the P-II MANGROVE trial to evaluate GLPG2737 vs PBO in a ratio (2:1) in 66 patients with ADPKD for 52wks. across 7 countries in the EU. The results are expected in H1’23
  • The primary objectives of the trial are to evaluate the effect on the growth of total kidney volume & to assess the overall safety and tolerability @52wks. while secondary objectives include renal function, PK, and PD
  • GLPG2737 is a CFTR inhibitor & is indicated to reduce cyst growth and kidney enlargement for patients with ADPKD. Additionally, the therapy was generally well-tolerated in previous clinical trials for patients with the same indication

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Analist


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions